On December 13th the Galway Neuroscience Cluster, based within the National Centre for Biomedical Engineering Science, held its annual research meeting.

NFB postgraduate researcher Shane Browne has been awarded a prestigious scholarship from the German Academic Exchange Service (DAAD) to advance his research for the treatment of myocardial infarction (MI). Through a collaboration with Prof. Katja Schenke-Layland, Shane will spend time at the Franhofer IGB Institute and the University of Tübingen in Stuttgart, Germany.

NFB fourth-year PhD student, Ben Newland, presented his research into “Designing Injectable Materials for Applications in Parkinson’s Disease” at the 2012 Roche Research Award in Life Sciences and Bioengineering which were held in NUI Galway on Monday November 19th.

A consortium led by the Network of Excellence for Functional Biomaterials (NFB) at NUI Galway has secured €3.7 million to fund research into a medical condition called ischemia. The condition occurs when blood supply to a tissue is limited, an example being ischemic heart disease, the most common cause of death in the western world, from which 16 million European adults currently suffer.

Tuesday, 5 November, 2012: Ireland-India research relations have been further strengthened by the signing of agreements between the Network of Excellence for Functional Biomaterials (NFB) at NUI Galway and four Indian institutions. Memorandums of Collaboration (MOC) have been agreed between NFB and the institutes, all four of which are instrumental in supporting the medical device and biotechnology sectors in India.

Tuesday, 30 October, 2012: Viscus Biologics LLC, Cleveland, Ohio, has secured an 18-month option to conduct further research into the development and commercialisation of a new tissue repair material developed by the Network of Excellence for Functional Biomaterials (NFB) at National University of Ireland, Galway. Research on the technology is being carried out by Viscus Biologics at its facility in Cleveland, Ohio.

A start-up medical device company that has been spun out from an NUI Galway research laboratory has begun an expansion that should see it double in size by the end of the year.

 A new type of cardiovascular stent, coated in antibodies to improve biocompatibility and effectiveness, is now under development in Ireland and Poland. Scientists at National University of Ireland Galway are to lead a €1.2 million EU project which aims to reduce re-narrowing of arteries and the need for further interventions, through the development of novel cardiovascular stent materials.

 Thursday, 20 September, 2012: The 3rd Annual Tissue Engineering and Regenerative Medicine (TERMIS) World Congress took place from 5-8 September in Vienna, Austria. Attracting over 2000 attendees, the congress has once again featured a strong display of field-leading research conducted by researchers at the Network of Excellence for Functional Biomaterials (NFB), NUI Galway.

 NUI GALWAY (NUIG) will share and exchange research on biomaterials with a leading Chinese research institute and a medical technology firm after signing a deal in Beijing today.

Minister for Health Dr James Reilly is due to attend the memorandum of understanding signing by NUIG’s president, Dr Jim Browne, with the Tianjin International Academy of Biotechnology and Medicine and China Nucleon Medical Technology Group.